The tweet was deleted by the author.
But we saved everything 🙂.
REGENXBIO participated in a weekend event hosted by CureDuchenne, bringing together families, patients, and researchers for a day dedicated to learning and building connections.
The gathering spotlighted the urgent need for new therapeutic approaches in Duchenne muscular dystrophy and provided a direct channel for REGENXBIO to engage with the affected community. The company reaffirmed its commitment to advancing innovative solutions aimed at improving the lives of those with Duchenne. Details on specific project updates or research outcomes from the event have not been disclosed.
REGENXBIO recently expanded its AFFINITY DUCHENNE study, putting patient and family support at the center of its clinical development process, according to a previous report. The company is also scheduled to present new clinical trial data for its RGX-202 gene therapy at the 2026 MDA Clinical and Scientific Conference, as detailed in an earlier update. Both efforts reflect an ongoing focus on research and community engagement.